SCHEMBL4770152

SCHEMBL4770152

CN(Cc1ccccc1)c1cc[c]cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.43
TSHR P16473 2/20 0.43
MAPT P10636 2/20 0.43
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 2/20 0.42
AOC3 Q16853 1/20 0.40
KDM4E B2RXH2 3/20 0.40
LMNA P02545 3/20 0.40
HTT P42858 2/20 0.40
GAA P10253 1/20 0.40
ERAP1 Q9NZ08 1/20 0.39
CHRM2 P08172 1/20 0.39
ADRA2A P08913 1/20 0.39
ADRA2B P18089 1/20 0.39
ADRA2C P18825 1/20 0.39
DRD1 P21728 1/20 0.39
SLC6A2 P23975 1/20 0.39
HTR2A P28223 1/20 0.39
SLC6A4 P31645 1/20 0.39
ADRA1A P35348 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4778674 0.84 PKM (0.50) AOC3
SCHEMBL4857037 0.75 ADRA2B (0.44) SMN1; SMN2TSHRMAPTKMT2AALDH1A1
SCHEMBL4747138 0.75 CHRM2 (0.63) SMN1; SMN2TSHRMAPTKMT2AALDH1A1
SCHEMBL863542 0.73 TSHR (0.50) TSHRALDH1A1AOC3LMNAADRA2B
SCHEMBL2474873 0.72 POLB (0.46) ALDH1A1KDM4EMAPK1
SCHEMBL182698 0.72
SCHEMBL11567282 0.71 GAA (0.49) SMN1; SMN2TSHRMAPTKMT2AALDH1A1
SCHEMBL17316687 0.71
SCHEMBL4774563 0.71 POLB (0.54) SMN1; SMN2TSHRMAPTKMT2AKDM4E
SCHEMBL2033967 0.70 DGAT1 (0.37) ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1991530-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP claimed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 US claimed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO claimed
EP-1991530-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP disclosed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 US disclosed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265256-A1 Phosphodiesterase 10 inhibitors PDE7A, PDE7B, PDE10A SMN1; SMN2 4053/4885TSHR 2811/4885MAPT 3278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.